Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis

Key Findings

• ●Avapritinib induced 30% molecular response (KIT D816V undetectable) in AdvSM
• ●Deep responses across ASM, SM-AHN, and MCL subtypes

Referenced in (1 disease)